PMID- 22886030
OWN - NLM
STAT- MEDLINE
DCOM- 20130726
LR  - 20220318
IS  - 1861-0692 (Electronic)
IS  - 1861-0684 (Linking)
VI  - 102
IP  - 2
DP  - 2013 Feb
TI  - Galectin-3 is an independent marker for ventricular remodeling and mortality in 
      patients with chronic heart failure.
PG  - 103-10
LID - 10.1007/s00392-012-0500-y [doi]
AB  - BACKGROUND: Galectin-3 (Gal-3) is a recently discovered marker for myocardial 
      fibrosis and elevated levels are associated with an impaired outcome after 
      short-term follow-up in heart failure (HF) patients. However, whether Gal-3 is 
      related to cardiac remodeling and outcome after long-term follow-up is unknown. 
      Therefore, we determined the utility of Gal-3 as a novel biomarker for left 
      ventricular remodeling and long-term outcome in patients with severe chronic HF. 
      METHODS AND RESULTS: A total of 240 HF patients with New York Heart Association 
      (NYHA) Class III and IV were included. Patients were followed for 8.7 +/- 1 years, 
      had a mean age of 71 +/- 0.6 years and 73 % of the study population was male. 
      Circulating levels of NT-proBNP and Gal-3 were measured. Serial echocardiography 
      was performed at baseline and at 3 months. At baseline median left ventricular 
      end-diastolic volume (LVEDV) was 267 mL [interquartile range 232-322]. Patients 
      were divided into three groups according to the change in LVEDV. Patients in whom 
      the LVEDV decreased over time had significant lower levels of Gal-3 at entry 
      compared to patients in whom the LVEDV was stable or increased (14.7 vs. 17.9 vs. 
      19.0 ng/mL; p = 0.004 for trend), whereas no significant differences were seen in 
      levels of NT-proBNP (p = 0.33). Multivariate linear regression analyses revealed 
      that Gal-3 levels were positively correlated to change in LVEDV (p = 0.007). In 
      addition, Gal-3 was a significant predictor of mortality after long-term 
      follow-up (p = 0.001). CONCLUSION: Gal-3 is associated with left ventricular 
      remodeling determined by serial echocardiography and predicts long-term mortality 
      in patients with severe chronic HF.
FAU - Lok, Dirk J
AU  - Lok DJ
AD  - Deventer Hospital, Nico Bolkesteinlaan 75, 7415 CM, Deventer, The Netherlands. 
      lokd@dz.nl
FAU - Lok, Sjoukje I
AU  - Lok SI
FAU - Bruggink-Andre de la Porte, Pieta W
AU  - Bruggink-Andre de la Porte PW
FAU - Badings, Erik
AU  - Badings E
FAU - Lipsic, Eric
AU  - Lipsic E
FAU - van Wijngaarden, Jan
AU  - van Wijngaarden J
FAU - de Boer, Rudolf A
AU  - de Boer RA
FAU - van Veldhuisen, Dirk J
AU  - van Veldhuisen DJ
FAU - van der Meer, Peter
AU  - van der Meer P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120812
PL  - Germany
TA  - Clin Res Cardiol
JT  - Clinical research in cardiology : official journal of the German Cardiac Society
JID - 101264123
RN  - 0 (Biomarkers)
RN  - 0 (Galectin 3)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Chronic Disease
MH  - Female
MH  - Galectin 3/*blood
MH  - Heart Failure/*blood/diagnostic imaging/*mortality/physiopathology
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Linear Models
MH  - Male
MH  - Multivariate Analysis
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Stroke Volume
MH  - Time Factors
MH  - Ultrasonography
MH  - *Ventricular Function, Left
MH  - *Ventricular Remodeling
EDAT- 2012/08/14 06:00
MHDA- 2013/07/28 06:00
CRDT- 2012/08/14 06:00
PHST- 2012/04/27 00:00 [received]
PHST- 2012/07/24 00:00 [accepted]
PHST- 2012/08/14 06:00 [entrez]
PHST- 2012/08/14 06:00 [pubmed]
PHST- 2013/07/28 06:00 [medline]
AID - 10.1007/s00392-012-0500-y [doi]
PST - ppublish
SO  - Clin Res Cardiol. 2013 Feb;102(2):103-10. doi: 10.1007/s00392-012-0500-y. Epub 
      2012 Aug 12.